Fulvestrant (‚Faslodex‘) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Veröffentlicht vonadmin 27. Juli 2020 Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R. http://www.ncbi.nlm.nih.gov/pubmed/17295045